SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2012

Notes To Consolidated Financial Statement [Abstract]

SUBSEQUENT EVENTS

22.       SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date of issuance of its condensed consolidated financial statements.

On October 8, 2012, the Company entered into a Settlement and Termination Agreement (the “Agreement”) with Revance to settle litigation and terminate certain contractual relationships between the Company and Revance. Pursuant to the terms of the Agreement, (i) the option to acquire Revance or to exclusively license certain of Revance's topical botulinum toxin products purchased by the Company on December 11, 2007 and (ii) the License Agreement dated July 28, 2009 between the Company and Revance have been terminated. In accordance with the Agreement, the previously disclosed litigation filed by Revance against the Company in the Court of Chancery of the State Delaware and the Company's counterclaims were dismissed with prejudice and all claims under the terminated agreements, whether known or unknown, were released. The Agreement also provides for an upfront payment to the Company of $7.0 million to be made within 30 days of the Agreement, payments to the Company of up to $14.0 million to be made upon certain Revance capital raising achievements and a payment to the Company of $4.0 million to be made upon the achievement of certain regulatory milestones.